Cytotoxic chemotherapy has long been the backbone of treatment for colorectal cancer (CRC) in patients. In spite of advances in therapy, the 5-year survival rate is still unsatisfactory, mostly due to chemotherapy resistance in the therapy process. In our study, we demonstrated that the fat mass and obesity-associated (FTO) protein promotes CRC progression and increases chemotherapy resistance, thus, targeting FTO is a promising strategy for therapy CRC, which not only blocks tumor growth, but also reverses chemotherapy resistance.
https://doi.org/10.1002/ctm2.772
